Most Read from past 24 hours






Over the weekend, my attention was drawn to an old Christmas carol whose words were composed by Henry Wadsworth Longfellow. I was particularly struck by the air of hopelessness which comes near the end of the carol, I Heard the Bells on Christmas Day: “And in despair I bowed my head; ‘There is no peace
READ MORE
The FDA recently added a warning to the puberty blockers used by transgender children, reports The Post-Millennial. The warning was added after the FDA identified “a serious potential side effect” that can “cause cause a dangerous surge of spinal fluid pressure in the brain,” as well as “headaches, nausea, double vision, and even permanent vision
READ MORE
The FDA recently authorized Pfizer’s and Moderna’s COVID-19 vaccines for children as young as six months. Troublingly, the evidence the FDA used for those decisions violates at least three safety and efficacy standards from earlier FDA publications about COVID-19 vaccines: In 2021, the FDA warned that “antibody tests should not be used to evaluate a
READ MORE
Last August, the U.S. Food and Drug Administration began testing MDMA (ecstasy) for treating post-traumatic stress disorder. The FDA also granted MDMA breakthrough therapy status to expedite the approval process by making it easier for drugmakers to begin clinical trials. Recently, MDMA passed phase 2 of the FDA’s four-phase drug-approval process. Although phase 3 requires
READ MORE
The FBI’s raid on former president Donald Trump’s Mar-a-Lago estate—ever so conveniently timed as the White House occupant’s approval numbers sink, the Swamp prepares to shovel a whopping $5.5 billion in foreign and military aid down the bottomless Ukrainian black hole and the American economy keels over like Biden on a bike—gives us a national
READ MORE
The Federal Bureau of Investigation recently disavowed a report from its Richmond field office which attempted to link traditional Catholicism to so-called white supremacy. FBI headquarters provided the following statement to The Washington Examiner on Thursday: While our standard practice is to not comment on specific intelligence products, this particular field office product — disseminated
READ MORE